EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oncopeptides AB's Enterprise Value is €48.89 Mil.
Oncopeptides AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-17.76 Mil. Therefore, Oncopeptides AB's EV-to-FCF for today is -2.75.
The historical rank and industry rank for Oncopeptides AB's EV-to-FCF or its related term are showing as below:
FRA:OND'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.24 Med: -1.34 Max: 0.27
Current: -2.85
During the past 12 years, the highest EV-to-FCF of Oncopeptides AB was 0.27. The lowest was -7.24. And the median was -1.34.
FRA:OND's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 15.57
vs FRA:OND: -2.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncopeptides AB's PE Ratio (TTM) for today is calculated as:
Oncopeptides AB's share price for today is €0.1379.
Oncopeptides AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Oncopeptides AB EV-to-FCF Related Terms
Oncopeptides AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncopeptides AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's EV-to-FCF falls into.
Oncopeptides AB's current Enterprise Value is €48.89 Mil.
Oncopeptides AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (FRA:OND) has a EV-to-FCF of -2.75 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #999999 out of 331 companies in the Biotechnology industry.
Is Oncopeptides AB's EV-to-FCF too high?
Oncopeptides AB's current EV-to-FCF is -2.75. Based on the distribution chart, Oncopeptides AB ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncopeptides AB has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #999999 out of 331 companies for EV-to-FCF. This places Oncopeptides AB in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current EV-to-FCF is -2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.36, compared to a current price of €0.14 — trading 61.7% below its estimated fair value. The current EV-to-FCF is -2.75. Oncopeptides AB's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current EV-to-FCF is -2.75 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 61.7% below its estimated GF Value™ of €0.36.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
EV-to-FCF: -2.75
GF Value™: €0.36 vs. price of €0.14 (61.7% below fair value)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
31GF Score
Get the complete analysis for FRA:OND
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
